The company – led by Mark McKenna, formerly chief executive of Prometheus Bio, which was sold to MSD for $10.8 billion ... which develops small-molecule kinase inhibitors for cancer, revealed ...

A lending group took back the One Lincoln office tower in downtown Boston on Friday with a $400 million bid at a foreclosure ...

Immutep (IMMP) announces an upcoming poster presentation for the TACTI-004 Phase III trial. The poster will be presented at the European Lung ...

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...

The 5977A MSD includes a new, highly sensitive Extractor Ion Source for higher Signal-to-Noise (SNR) and a statistically based, low-femtogram Instrument Detection Limit (IDL). Skip to content Menu ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending ...

which included two phase 3 trials - KeyVibe-003 and KeyVibe-007 - in patients with non-small cell lung cancer (NSCLC). MSD, known as Merck & Co in the US and Canada, said the studies' independent ...

In response to the surging global demand for pre-owned goods, international technology firm Ronati has launched Studio, a ...

Unique Therapeutic Potential: ATG-022 is a highly differentiated ADC demonstrated efficacy across the broadest range of CLDN18.2 expression levels. Clinical data show that ATG-022 not only ...

"Studio marks a new era of empowerment for these small businesses and resellers. Our goal is to enable them to easily, efficiently, and effectively document, organize, and manage their constantly ...

She also introduced a new logo for the company comprised of a palm tree with two hummingbirds flapping their wings on either side of it. However, a small Mallorcan village, Porreres, in Spain is ...